John W. Park focuses on Liposome, Pharmacology, Drug delivery, In vivo and Drug carrier. His Liposome research includes themes of Immunoliposome, Glioma, Molecular biology, Targeted drug delivery and Oligonucleotide. John W. Park has included themes like Internalization, Transplantation, Biodistribution and Doxorubicin in his Immunoliposome study.
The study incorporates disciplines such as Breast cancer, Personalized medicine and Intensive care medicine in addition to Pharmacology. His studies in Drug delivery integrate themes in fields like Irinotecan, Enzyme inhibitor and Drug. His Drug carrier research incorporates elements of Confocal microscopy and Therapeutic index.
John W. Park mainly focuses on Breast cancer, Internal medicine, Oncology, Cancer and Liposome. His Breast cancer study combines topics from a wide range of disciplines, such as Stage, Surgery, Cancer research and Pathology. His work deals with themes such as Clinical endpoint, Neratinib, Trastuzumab and Circulating tumor cell, which intersect with Oncology.
His Liposome study integrates concerns from other disciplines, such as Drug delivery, Drug carrier, Doxorubicin, Pharmacology and In vivo. John W. Park combines subjects such as Immunoliposome and Biodistribution with his study of Drug delivery. His study in Pharmacology is interdisciplinary in nature, drawing from both Brain tumor and Irinotecan.
Internal medicine, Oncology, Circulating tumor cell, Breast cancer and Cancer are his primary areas of study. His studies deal with areas such as Cancer research, Tumor cells, Metastatic breast cancer, Molecular biology and Bone marrow as well as Circulating tumor cell. His work on Neoadjuvant therapy as part of general Breast cancer research is frequently linked to Context, thereby connecting diverse disciplines of science.
His Cancer research is multidisciplinary, incorporating elements of Radiation therapy and Median follow-up. His Preclinical data research is multidisciplinary, relying on both Pazopanib and Pharmacology. His Irinotecan research is multidisciplinary, incorporating perspectives in Drug, Pharmacokinetics, Liposome and Glioma.
John W. Park mostly deals with Breast cancer, Internal medicine, Oncology, Circulating tumor cell and Biomarker. The various areas that John W. Park examines in his Breast cancer study include Clinical endpoint, Protein kinase B and Proportional hazards model. He interconnects Irinotecan and Estrogen in the investigation of issues within Oncology.
His Circulating tumor cell study is concerned with the field of Cancer as a whole. His Biomarker research incorporates themes from Cancer research, Clinical trial, Trastuzumab, Metastatic breast cancer and Metastasis. The Chemotherapy study combines topics in areas such as Glioma, Liposome and Pharmacology, Drug.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl;Lyndon Kim;Kraig Moore;Paul Duic.
Journal of Clinical Oncology (2009)
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Dmitri B. Kirpotin;Daryl C. Drummond;Yi Shao;M. Refaat Shalaby.
Cancer Research (2006)
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
John W Park;Keelung Hong;Dmitri B Kirpotin;Gail Colbern.
Clinical Cancer Research (2002)
Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results
Hope S. Rugo;Roy S. Herbst;Glenn Liu;John W. Park.
Journal of Clinical Oncology (2005)
STERICALLY STABILIZED ANTI-HER2 IMMUNOLIPOSOMES : DESIGN AND TARGETING TO HUMAN BREAST CANCER CELLS IN VITRO
Dmitri Kirpotin;John W. Park;Keelung Hong;Samuel Zalipsky.
The cancer glycocalyx mechanically primes integrin-mediated growth and survival
Matthew J. Paszek;Christopher C. DuFort;Olivier Rossier;Russell O Bainer.
Liposome-based drug delivery in breast cancer treatment.
John W Park.
Breast Cancer Research (2002)
Subtype and pathway specific responses to anticancer compounds in breast cancer.
Laura M. Heiser;Anguraj Sadanandam;Wen-Lin Kuo;Stephen C. Benz.
Proceedings of the National Academy of Sciences of the United States of America (2012)
Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells
Christoph Mamot;Daryl C Drummond;Udo Greiser;Keelung Hong.
Cancer Research (2003)
Development of anti-p185HER2 immunoliposomes for cancer therapy.
J W Park;K Hong;P Carter;H Asgari.
Proceedings of the National Academy of Sciences of the United States of America (1995)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: